Julián Torre‐Cisneros

9.8k total citations · 2 hit papers
141 papers, 4.7k citations indexed

About

Julián Torre‐Cisneros is a scholar working on Epidemiology, Infectious Diseases and Molecular Medicine. According to data from OpenAlex, Julián Torre‐Cisneros has authored 141 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Epidemiology, 45 papers in Infectious Diseases and 32 papers in Molecular Medicine. Recurrent topics in Julián Torre‐Cisneros's work include Cytomegalovirus and herpesvirus research (39 papers), Antibiotic Resistance in Bacteria (32 papers) and Herpesvirus Infections and Treatments (24 papers). Julián Torre‐Cisneros is often cited by papers focused on Cytomegalovirus and herpesvirus research (39 papers), Antibiotic Resistance in Bacteria (32 papers) and Herpesvirus Infections and Treatments (24 papers). Julián Torre‐Cisneros collaborates with scholars based in Spain, United States and Italy. Julián Torre‐Cisneros's co-authors include Antonio Rivero, José María Aguado, Juan José Castón, G. Just‐Nübling, Haran T. Schlamm, Thomas J. Walsh, B. Dupont, Ana Espinel‐Ingroff, Elizabeth M. Johnson and John R. Perfect and has published in prestigious journals such as PLoS ONE, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Julián Torre‐Cisneros

135 papers receiving 4.6k citations

Hit Papers

Efficacy and safety of ce... 2003 2026 2010 2018 2020 2003 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
    2020 540 citations Julián Torre‐Cisneros et al. profile →
  2. Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
    2003 508 citations John R. Perfect, Kieren A. Marr et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julián Torre‐Cisneros Spain 33 2.8k 1.7k 1.2k 760 564 141 4.7k
Satoshi Ichiyama Japan 39 2.4k 0.8× 1.9k 1.1× 1.7k 1.4× 534 0.7× 338 0.6× 217 5.8k
Fernanda P. Silveira United States 36 2.9k 1.0× 1.6k 1.0× 1.4k 1.1× 1.0k 1.3× 323 0.6× 96 4.7k
Carlos Cervera Spain 42 3.0k 1.1× 1.6k 1.0× 487 0.4× 433 0.6× 126 0.2× 163 4.5k
Kwen‐Tay Luh Taiwan 48 2.0k 0.7× 1.8k 1.1× 1.1k 0.9× 400 0.5× 371 0.7× 149 6.0k
Jun Hee Woo South Korea 39 3.0k 1.1× 3.1k 1.9× 849 0.7× 422 0.6× 241 0.4× 297 6.0k
Francesco Menichetti Italy 37 1.7k 0.6× 1.6k 0.9× 1.5k 1.2× 1.0k 1.3× 633 1.1× 111 4.2k
Shirish Huprikar United States 24 1.8k 0.6× 886 0.5× 761 0.6× 378 0.5× 225 0.4× 80 2.9k
Juan J. Picazo Spain 34 1.7k 0.6× 1.9k 1.1× 962 0.8× 570 0.8× 341 0.6× 156 4.2k
Susan Whittier United States 41 1.5k 0.5× 1.9k 1.1× 973 0.8× 342 0.5× 391 0.7× 118 4.7k
Valerio Del Bono Italy 32 1.4k 0.5× 962 0.6× 1.0k 0.8× 639 0.8× 481 0.9× 80 2.8k

Countries citing papers authored by Julián Torre‐Cisneros

Since Specialization
Citations

This map shows the geographic impact of Julián Torre‐Cisneros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julián Torre‐Cisneros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julián Torre‐Cisneros more than expected).

Fields of papers citing papers by Julián Torre‐Cisneros

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julián Torre‐Cisneros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julián Torre‐Cisneros. The network helps show where Julián Torre‐Cisneros may publish in the future.

Co-authorship network of co-authors of Julián Torre‐Cisneros

This figure shows the co-authorship network connecting the top 25 collaborators of Julián Torre‐Cisneros. A scholar is included among the top collaborators of Julián Torre‐Cisneros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julián Torre‐Cisneros. Julián Torre‐Cisneros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Machuca, Isabel, Irene Gracia-Ahufinger, Rafael Ruiz-Montero, et al.. (2024). Long-Term Clinical and Ecological Impact of an Antimicrobial Stewardship Program on the Incidence of Carbapenem-Resistant Klebsiella pneumoniae Infections in a High-Endemic Hospital. Antibiotics. 13(9). 792–792. 1 indexed citations
2.
Fernández‐Ruiz, Mario, Juan José Castón, José Luís del Pozo, et al.. (2024). ¿Cómo podemos optimizar el abordaje diagnóstico y terapéutico de la neumonía? Recomendaciones basadas en una opinión de expertos. Enfermedades Infecciosas y Microbiología Clínica. 42(8). 442–452.
3.
Merino, N., Isabel Machuca, Julia Guzmán-Puche, et al.. (2023). Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria. International Journal of Antimicrobial Agents. 62(1). 106818–106818. 9 indexed citations
4.
Pérez, Ana Belén, et al.. (2023). Real-life experience in two cases of secondary prophylaxis with letermovir for CMV infection in solid organ transplantation. Microbiology Spectrum. 11(6). e0163023–e0163023. 5 indexed citations
5.
Merchante, Nicolás, et al.. (2022). Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial. idUS (Universidad de Sevilla). 25 indexed citations
6.
Peñalva, Germán, Juan José Castón, Ángela Cano, et al.. (2021). Impact of an Antimicrobial Stewardship Program on the Incidence of Carbapenem Resistant Gram-Negative Bacilli: An Interrupted Time-Series Analysis. Antibiotics. 10(5). 586–586. 12 indexed citations
7.
Escudero-Sánchez, Rosa, María Ruiz‐Ruigómez, Sergio García‐Fernández, et al.. (2020). Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection. Journal of Clinical Medicine. 10(1). 2–2. 20 indexed citations
8.
Bleriot, Inés, Rocío Trastoy, Lucía Blasco, et al.. (2020). Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of Klebsiella pneumoniae. Microbial Genomics. 6(5). 26 indexed citations
9.
10.
Cantisán, Sara, M.L. Agüera, Marta Suñer, et al.. (2020). Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation. The Journal of Infectious Diseases. 223(7). 1205–1213. 5 indexed citations
11.
12.
Martín‐Dávila, Pilar, et al.. (2017). Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. International Journal of Infectious Diseases. 59. 118–123. 119 indexed citations
13.
Machuca, Isabel, Irene Gracia-Ahufinger, Elena Pérez‐Nadales, et al.. (2017). The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clinical Microbiology and Infection. 24(6). 630–634. 39 indexed citations
14.
Viasus, Diego, José Ramón Paño‐Pardo, Jerónimo Pachón, et al.. (2011). Pneumonia Complicating Pandemic (H1N1) 2009. Medicine. 90(5). 328–336. 30 indexed citations
15.
Pérez‐Camacho, Inés, Ángela Camacho, Julián Torre‐Cisneros, & Antonio Rivero. (2009). Factores de riesgo cardiovascular dependientes del tratamiento antirretroviral. Enfermedades Infecciosas y Microbiología Clínica. 27. 24–32. 2 indexed citations
16.
Ramos, António, Ángel Asensio, Elena Múñez, et al.. (2008). Incisional surgical infection in heart transplantation. Transplant Infectious Disease. 10(4). 298–302. 21 indexed citations
17.
Palacios, Rosario, Antonio Rivero, Juan Macı́as, et al.. (2006). Low Incidence of Severe Liver Events in HIV Patients With and Without Hepatitis C or B Coinfection Receiving Lopinavir/Ritonavir. HIV Clinical Trials. 7(6). 319–323. 1 indexed citations
18.
Perfect, John R., Kieren A. Marr, Thomas J. Walsh, et al.. (2003). Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections. Clinical Infectious Diseases. 36(9). 1122–1131. 508 indexed citations breakdown →
19.
Laguna, Fernando Ballester, Rogelio López‐Vélez, Federico Pulido, et al.. (1999). Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS. 13(9). 1063–1069. 99 indexed citations
20.
López‐Miranda, José, et al.. (1991). THE EFFECT OF CYCLOSPORINE ON EXOCRINE FUNCTION OF THE RAT PANCREAS—AN IN VITRO STUDY. Transplantation. 51(3). 562–565. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Satoshi Ichiyama Breakdown of academic impact, for papers by Fernanda P. Silveira Breakdown of academic impact, for papers by Carlos Cervera Breakdown of academic impact, for papers by Kwen‐Tay Luh Breakdown of academic impact, for papers by Jun Hee Woo Breakdown of academic impact, for papers by Francesco Menichetti Breakdown of academic impact, for papers by Shirish Huprikar Breakdown of academic impact, for papers by Juan J. Picazo Breakdown of academic impact, for papers by Susan Whittier Breakdown of academic impact, for papers by Valerio Del Bono
Rankless by CCL
2026